Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor–positive metastatic breast cancer

References

• 1. Howlader N, Altekruse SF, Li CI et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl. Cancer Inst. 106(5), 1507–1516 (2014).
  Google Scholar
• 2. Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat. Rev. 59, 22–32 (2017).
  Medline CASGoogle Scholar
• 3. O'leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 13(7), 417–430 (2016).
  MedlineGoogle Scholar
• 4. Vora SR, Juric D, Kim N et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 26(1), 136–149 (2014).
  Medline CASGoogle Scholar
• 5. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer. 17(2), 93–115 (2017).
  Medline CASGoogle Scholar
• 6. Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? Oncology. 32(5), 216–222 (2018).
  MedlineGoogle Scholar
• 7. Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 1925–1936 (2016).
  Medline CASGoogle Scholar
• 8. Cristofanilli M, Turner NC, Bondarenko I et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 17(4), 425–439 (2016).
  Medline CASGoogle Scholar
• 9. Hortobagyi GN, Stemmer SM, Burris HA et al. Updated results from MONALEESA-2, a Phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 30(11), 1842 (2019).
  Medline CASGoogle Scholar
• 10. Slamon DJ, Neven P, Chia S et al. Human epidermal growth factor 2-negative advanced breast cancer treated with fulvestrant ± ribociclib. Esmo Congress 2019. Abstract Lba7_Pr. September 29, 2019.
  Google Scholar
• 11. Im SA, Lu YS, Bardia A. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med. 5(381), 307–316 (2019).
  Google Scholar
• 12. Sledge GW Jr, Toi M, Neven P et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35(25), 2875–2884 (2017).
  Medline CASGoogle Scholar
• 13. Johnston S, Martin M, Di Leo A et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 5, 5 (2019).
  MedlineGoogle Scholar
• 14. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised Phase 2 study. Lancet Oncol. 16(1), 25–35 (2015).
  Medline CASGoogle Scholar
• 15. Finn RS, Crown J, Lang I et al. Overall survival results from the randomized Phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). J. Clin. Oncol. 35(15s), 1001 (2017).
  Google Scholar
• 16. Turner NC, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373(3), 209–219 (2015).
  Medline CASGoogle Scholar
• 17. Goetz MP, Toi M, Campone M et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 35(32), 3638–3646 (2017).
  Medline CASGoogle Scholar
• 18. Sledge GW, Toi M, Neven P et al. Her2- advanced breast cancer. ESMO Congress 2019. Abstract Lba6_Pr. September 29, 2019.
  Google Scholar
• 19. Sledge GW Jr., Toi M, Neven P et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6(1), 116–124 (2020).
  MedlineGoogle Scholar
• 20. Hamilton E, Cortes J, Dieras V et al. nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer. 2018 San Antonio Breast Cancer Symposium. 79(4), 215–222 (2018).
  Google Scholar
• 21. Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 29(1), 101–111 (2018).
  Medline CASGoogle Scholar
• 22. Turner NC, Slamon DJ, Ro J et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer N. Engl. J. Med. 379(20), 1926–1936 (2018).
  Medline CASGoogle Scholar
• 23. Anders CK, Rhun Le E, Bachelot TD et al. A Phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). J. Clin. Oncol. 37(15), 1017 (2019).
  Google Scholar
• 24. Park YH, Kim YT, Kim GM et al. A randomized Phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746). ASCO 2019 37(15), 1007 (2019).
  Google Scholar
• 25. Martín M, Zielinski C, Ruíz-Borrego M et al. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A Phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). 2019 San Antonio Breast Cancer Symposium (SABCS) (Abstract GS2-07), (2019).
  Google Scholar
• 26. Chandarlapaty S, Razavi P. Cyclin E mRNA: assessing cyclin-dependent kinase (CDK) activation state to elucidate breast cancer resistance to CDK4/6 inhibitors. J. Clin. Oncol. 37(14), 1148–1150 (2019).
  MedlineGoogle Scholar
• 27. Turner NC, Liu Y, Zhu Z et al. Cyclin E1 Expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer. J. Clin. Oncol. 37(14), 1169–1178 (2019).
  Medline CASGoogle Scholar
• 28. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife. 3, 1329–1338 (2014).
  Google Scholar
• 29. Formisano L, Lu Y, Servetto A et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 10(1), 1373 (2019).
  MedlineGoogle Scholar
• 30. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 18(2), 753–761 (1998).
  Medline CASGoogle Scholar
• 31. Thangavel C, Boopathi E, Liu Y et al. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non-small cell lung cancer. Clin. Cancer Res. 24(6), 1402–1414 (2018).
  Medline CASGoogle Scholar
• 32. US FDA. FDA approves alpelisib for metastatic breast cancer (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer
  Google Scholar
• 33. Andre F, Ciruelos E, Rubovszky G et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380(20), 1929–1940 (2019).
  Medline CASGoogle Scholar
• 34. Kornblum N, Zhao F, Manola J et al. Randomized Phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J. Clin. Oncol. 36(16), 1556–1563 (2018).
  Medline CASGoogle Scholar
• 35. Dickler MN, Tolaney SM, Rugo HS et al. MONARCH 1, a Phase ii study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin. Cancer Res. 23(17), 5218–5224 (2017).
  Medline CASGoogle Scholar
• 36. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226), 817–827 (2020).
  Medline CASGoogle Scholar
• 37. Sammons S, Shastry M, Dent S, Anders C, Hamilton E. Practical treatment strategies and future directions after progression while receiving CDK4/6 inhibition and endocrine therapy in advanced HR(+)/HER2(−) breast cancer. Clin. Breast Cancer 20(1), 1–11 (2020).
  Medline CASGoogle Scholar
• 38. Gluck S. Consequences of the convergence of multiple alternate pathways on the estrogen receptor in the treatment of metastatic breast cancer. Clin. Breast Cancer 17(2), 79–90 (2017).
  Medline CASGoogle Scholar
• 39. Jones RH, Casbard A, Carucci M et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, Phase 2 trial. Lancet Oncol. 21(3), 345–357 (2020).
  Medline CASGoogle Scholar
• 40. Goel S, Wang Q, Watt AC et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29(3), 255–269 (2016).
  Medline CASGoogle Scholar
• 41. Finn Rs AA, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18(17), 1216–1225 (2016).
  Google Scholar
• 42. Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372(8), 724–734 (2015).
  Medline CASGoogle Scholar
• 43. Rimawi M, Ferrero JM, De La Haba-Rodriguez J et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label Phase II trial. J. Clin. Oncol. 36(28), 2826–2835 (2018).
  Medline CASGoogle Scholar
• 44. PATINA trial: randomized, open label, clinical study of the targeted therapy, palbociclib, to treat metastatic breast cancer (2020). https://clinicaltrials.gov/ct2/show/NCT02947685
  Google Scholar
• 45. Goel S, Decristo MJ, Watt AC et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548(7668), 471–475 (2017).
  Medline CASGoogle Scholar
• 46. Ma CX, Gao F, Luo J et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23(15), 4055–4065 (2017).
  Medline CASGoogle Scholar
• 47. Martin MHS, Chan D, Fernandez-Abad M, Petru E, Rostorfer R et al. Final results of NeoMONARCH: A Phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). 2018 AACR Meeting 78, 645–657 (2018).
  Google Scholar